CAJ | 학술논문

目的：探讨纤维连接蛋白(Fn)和HBV基因分型(B型、C型、D型)的联合检测在肝病诊疗中的意义。方法对264例HBV感染患者采用单向免疫扩散法进行血清Fn的检测,并行荧光PCR检测；采用核酸测序法进行HBV基因分型(B型、C型、D型)检测,同时与200例健康体检者(对照组)的血清进行比较。结果264例HBV感染患者中慢性活动性肝炎和慢性迁延性肝炎患者的血清Fn与对照组比较,差异无统计学意义(P>0.05)；血清Fn下降最明显的是重度肝炎患者,与对照组比较,差异有统计学意义(P<0.01)；急性肝炎、肝硬化以及肝癌患者血清Fn均明显下降,与对照组比较,差异有统计学意义(P<0.05)。HBV基因型为B型患者共138例,C型患者46例,D型患者21例,B、D混合型患者59例。结论 Fn和HBV基因分型的联合检测能够比较客观地反映患者各项检测指标的达标情况,有助于对患者体内病毒的复制状态进行准确了解,进而为临床治疗提供方案。
목적：탐토섬유련접단백(Fn)화HBV기인분형(B형、C형、D형)적연합검측재간병진료중적의의。방법대264례HBV감염환자채용단향면역확산법진행혈청Fn적검측,병행형광PCR검측；채용핵산측서법진행HBV기인분형(B형、C형、D형)검측,동시여200례건강체검자(대조조)적혈청진행비교。결과264례HBV감염환자중만성활동성간염화만성천연성간염환자적혈청Fn여대조조비교,차이무통계학의의(P>0.05)；혈청Fn하강최명현적시중도간염환자,여대조조비교,차이유통계학의의(P<0.01)；급성간염、간경화이급간암환자혈청Fn균명현하강,여대조조비교,차이유통계학의의(P<0.05)。HBV기인형위B형환자공138례,C형환자46례,D형환자21례,B、D혼합형환자59례。결론 Fn화HBV기인분형적연합검측능구비교객관지반영환자각항검측지표적체표정황,유조우대환자체내병독적복제상태진행준학료해,진이위림상치료제공방안。
Objective To discuss the meaning of fibronectin test combined with HBV gene (type B,type C or type D) test in diagnosis and treatment of liver disease. Methods 264 HBV infected patients were provided with serum fi-bronectin (Fn) test by using single radial immunodiffusion method,and were provided with fluorescence PCR test and HBV genotype test by nucleic acid sequencing method (type B,type C or type D).Serums of 200 healthy persons were used as controls for comparison. Results In 264 HBV-infected patients,serum Fn of chronic active hepatitis patients and chronic persistent hepatitis patients was of no statistical difference compared with that in healthy people (P>0.05). Serum Fn of severe hepatitis patients decreased most obviously with high statistical difference compared with that in healthy people (P<0.01).Serum Fn of acute hepatitis patients,hepatic cirrhosis patients and liver cancer patients de-creased as well (P<0.05).There were 138 patients with type B,46 patients with type C,21 patients with type D and 59 patients with type B/D. Conclusion Fibronectin test combined with HBV genotype test can relatively objectively reflect whether the results of each test index of patients reach the set standard so that it can help accurately know the replica-tion status of virus in patients and provide clinical treatment regimens.